A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2006
11/07/2006	CA2248032C Serum cholesterol lowering agent
11/07/2006	CA2244777C 2,3-benzodiazepine derivatives and their use as ampa-receptor inhibitors
11/07/2006	CA2235264C Chiral methylphenyloxazolidinones
11/07/2006	CA2226436C Generation of immune responses to prostate-specific antigen (psa)
11/07/2006	CA2200578C N-substituted piperidinyl bicyclic benzoate derivatives
11/07/2006	CA2192824C Pyridone-carboxylic acid derivatives, processes for the preparation thereof and anti-tumor agents containing the pyridone-carboxylic acid derivatives
11/07/2006	CA2191664C Formulation for iron chelation, a process for preparing the formulation and a method of treating thalassemia
11/07/2006	CA2158268C N-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
11/07/2006	CA2146961C Heterobicyclic sulfonamide and sulfonic ester derivatives
11/07/2006	CA2130703C Diacyl-substituted guanidines, a process for their preparation, their use as medicine or diagnostic aid, and medicine containing them
11/05/2006	CA2545778A1 Synthesis and antiprotozoal activity of dicationic 3,5-diphenylisoxazoles
11/02/2006	WO2006116773A2 Methods, compositions, and compounds for modulation of monoacylglycerol lipase, pain, and stress-related disorders
11/02/2006	WO2006116764A1 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
11/02/2006	WO2006116755A2 Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
11/02/2006	WO2006116733A2 Protein kinase inhibitors
11/02/2006	WO2006116721A1 Ex vivo gene expression in whole blood as a model of assessment of individual variation to dietary supplements
11/02/2006	WO2006116716A2 Materials and methods for enhanced degradation of mutant proteins associated with human disease
11/02/2006	WO2006116713A1 Substituted amide derivatives as protein kinase inhibitors
11/02/2006	WO2006116703A2 Methods and models for stress-induced analgesia
11/02/2006	WO2006116655A2 Novel isovaleramide forms, compositions thereof, and related methods of use
11/02/2006	WO2006116630A2 Method for use of acetyl-l-carnitine ( alcar) for treatment of depressive disorders in humans
11/02/2006	WO2006116626A2 Methods and compositions for treating pain
11/02/2006	WO2006116615A1 Benzisoxazole piperazine compounds and methods of use thereof
11/02/2006	WO2006116614A1 Benzisoxazole piperidine compounds and methods of use thereof
11/02/2006	WO2006116596A2 Micronized tanaproget and compostions containing same
11/02/2006	WO2006116591A2 Ophthalmic formulations comprising prednisolone acetate and tobramycin and uses thereof
11/02/2006	WO2006116583A2 Compositions comprising a polymerized benzimidazole and a buffering agent and methods of using same
11/02/2006	WO2006116582A2 Pharmaceutical compositions comprising a substituted benzimidazole, buffering agent and vitamin b12
11/02/2006	WO2006116563A1 Vanilloid receptor ligands and their use in treatments
11/02/2006	WO2006116560A2 Surface active and interactive protein polymers and methods of making the same
11/02/2006	WO2006116557A1 Nucleoside compounds for treating viral infections
11/02/2006	WO2006116556A2 Composition comprising proton pump inhibitor and buffer
11/02/2006	WO2006116546A1 Surface-modified microparticles and methods of forming and using the same
11/02/2006	WO2006116532A2 Synthesis of oligo/poly(catechins) and methods of use
11/02/2006	WO2006116526A2 Polymorph form ii of tanaproget
11/02/2006	WO2006116514A2 Micronized tanaproget, compositions, and methods of preparing the same
11/02/2006	WO2006116512A1 Nucleoside compounds and methods of use thereof
11/02/2006	WO2006116499A1 4-biarylyl-1-phenylazetidin-2-one glucuronide derivatives for hypercholesterolemia
11/02/2006	WO2006116498A2 Purified form of tanaproget
11/02/2006	WO2006116486A2 Composition and method for reducing the appearance for cellulite
11/02/2006	WO2006116485A2 Trpv1 agonist compounds and methods for making and using the same
11/02/2006	WO2006116470A1 Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment
11/02/2006	WO2006116452A1 Nutritional composition comprising hyaluronic acid and superoxide dismutase and methods of making and using same
11/02/2006	WO2006116435A2 Methods of treating atherosclerosis
11/02/2006	WO2006116401A1 C-5 substituted quinazolinone derivatives as selective estrogen receptor beta modulators
11/02/2006	WO2006116399A2 Use of novel compounds for ibd treatment
11/02/2006	WO2006116355A1 Ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders
11/02/2006	WO2006116353A2 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
11/02/2006	WO2006116349A2 Sustained release formulation and dosing schedules of leukotriene synthesis inhibitor for human therapy
11/02/2006	WO2006116341A1 Method for treating advanced ovarian cancer with doxorubicin entrapped in liposomes
11/02/2006	WO2006116337A2 Doped semiconductor nanocrystals and methods of making same
11/02/2006	WO2006116322A2 Nicotinamide riboside kinase compositions and methods for using the same
11/02/2006	WO2006116311A2 Opioid receptor agonist compounds and their use in treatment of pain
11/02/2006	WO2006116262A1 Use of vitamin e tocotrienols for the inhibition of intracellularly obligate pathogen chlamydia
11/02/2006	WO2006116247A1 Extended release formulations
11/02/2006	WO2006116221A2 Therapeutic combinations for the treatment or prevention of psychotic disorders
11/02/2006	WO2006116218A1 Crystal forms of {[(2r)-7-(2,6-dichlorophenyl)-5-fluoro-2,3-dihydro-1-benzofuran-2-yl]methyl}amine hydrochloride
11/02/2006	WO2006116217A2 Therapeutic bifunctional compounds
11/02/2006	WO2006116204A1 Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin d compounds or mimics thereof
11/02/2006	WO2006116174A2 Pharmaceutical and therapeutic applications relating to a type 9 adenylyl cyclase
11/02/2006	WO2006116171A1 Treatment of pain
11/02/2006	WO2006116170A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	WO2006116169A2 Methods for modulating bladder function
11/02/2006	WO2006116165A1 Chromane and chromene derivatives and uses thereof
11/02/2006	WO2006116158A1 Benzodioxane and benzodioxolane derivatives and uses thereof
11/02/2006	WO2006116151A1 Benzofuranyl alkanamine derivatives and uses thereof as 5-ht2c agonists
11/02/2006	WO2006116150A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	WO2006116149A1 New therapeutic combianations for the treatment or prevention of depression
11/02/2006	WO2006116136A1 Dihydrobenzofuran derivatives and uses thereof
11/02/2006	WO2006115987A2 Use of a clobetasol spray formulation to treat psoriasis
11/02/2006	WO2006115918A2 Vla-4 antagonists
11/02/2006	WO2006115871A1 Extended estrogen dosing contraceptive regimen
11/02/2006	WO2006115845A1 Benzothiophene derivatives
11/02/2006	WO2006115835A2 Benzothiophene hydroxamic acid derivatives
11/02/2006	WO2006115834A1 Angiotensin ii receptor antagonists
11/02/2006	WO2006115833A1 Benzothiophene hydroxamic acid derivatives with carbamate, urea, amide and sulfonamide substitutions
11/02/2006	WO2006115770A2 Orally disintegrating pharmaceutical tablet formulations of olanzapine
11/02/2006	WO2006115743A2 Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
11/02/2006	WO2006115733A2 Elastin stabilization of connective tissue
11/02/2006	WO2006115713A2 Eutectic blends containing a water soluble vitamin derivative
11/02/2006	WO2006115652A1 Fluorinated pyridine n-oxide thrombin modulators and process for n-oxidation of nitrogen containing heteroaryls
11/02/2006	WO2006115548A2 Subunit vaccine against west nile viral infection
11/02/2006	WO2006115547A2 Dendritic polymers with enhanced amplification and interior functionality
11/02/2006	WO2006115509A2 Small molecule immunopotentiators and assays for their detection
11/02/2006	WO2006115494A1 Lyophilized azithromycin formulation
11/02/2006	WO2006115452A1 Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
11/02/2006	WO2006115436A1 Medicinal agent for preventing progression of apoptotic and jugulating necrotic changes in the organism tissues
11/02/2006	WO2006115423A1 Immune response inhibition using indole diterpene compound
11/02/2006	WO2006115413A2 Methods and means for the treatment of hpv induced intraepithelial neoplasias
11/02/2006	WO2006115412A2 Nutrition with lipids and non-digestible saccharides
11/02/2006	WO2006115353A1 A novel hydroxamic acid derivative as peptide deformylase inhibitor and manufacturing method thereof
11/02/2006	WO2006115307A1 Method of extracting ginsengnoside rg2m, pharmaceutical composition including ginsengnoside rg2, and uses thereof
11/02/2006	WO2006115304A1 Agent for treating neuropathic pain
11/02/2006	WO2006115302A1 Therapeutic agent for neuropathic pain
11/02/2006	WO2006115293A1 NOVEL BLOCK COPOLYMER USED FOR PREPARING pH-RESPONSIVE POLYMER MICELLE, AND METHOD FOR PRODUCING SAME
11/02/2006	WO2006115289A1 Combination of a cyanopyrrolidine with a hepatic gluconeogenesis inhibitor
11/02/2006	WO2006115286A1 Piperidine derivatives, crystal, process for producing the same, and use as tachikinin receptor antagonists
11/02/2006	WO2006115285A1 Pharmaceutical composition
11/02/2006	WO2006115279A1 Composition for preservation of vascular endothelium
11/02/2006	WO2006115274A1 Myeloerythroid progenitor differentiation inducer

1 ... 4022 4023 4024 4025 4026 4027 4028 4029 4030 4031 4032 4033 4034 4035 4036 4037 4038 4039 4040 4041 4042 ... 7860